About: Immune checkpoint inhibitors: A physiology-driven approach to the treatment of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immune checkpoint inhibitors: A physiology-driven approach to the treatment of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Immune checkpoint inhibitors: A physiology-driven approach to the treatment of COVID-19
Creator	Curigliano, Giuseppe Cortés, Javier Di Cosimo, Serena Llombart-Cussac, Antonio Malfettone, Andrea Manuel Pérez-García, José Miceli, Rosalba
source	Elsevier; Medline; PMC; WHO
abstract	While confirmed cases of infections of the deadly coronavirus disease 2019 (COVID-19) have exceeded 4.7 million globally, scientists are pushing forward with efforts to develop vaccines and treatments in an attempt to slow the pandemic and lessen the disease’s damage. Although no proven effective therapies to treat COVID-19 patients or for managing their complications currently exist, the rapidly expanding knowledge regarding severe acute respiratory syndrome–coronavirus 2 and its interplay with hosts provide a significant number of potential drug targets, and the potential to repurpose drugs already tested in other diseases. Herein we report the biological rationale of immuno-activating drugs and a brief summary of literature data on the potential therapeutic value of immune checkpoint inhibitors that have been recently tested beyond cancer treatment for their potential to restore cellular immuno-competence.
has issue date	2020-06-04(xsd:dateTime)
bibo:doi	10.1016/j.ejca.2020.05.026
bibo:pmid	32544799
has license	no-cc
sha1sum (hex)	4db3607a0dea04c4e1c3da4ae5bdd39a8435c9f1
schema:url	https://doi.org/10.1016/j.ejca.2020.05.026
resource representing a document's title	Immune checkpoint inhibitors: A physiology-driven approach to the treatment of COVID-19
has PubMed Central identifier	PMC7269953
has PubMed identifier	32544799
schema:publication	Eur J Cancer
resource representing a document's body	covid:4db3607a0dea04c4e1c3da4ae5bdd39a8435c9f1#body_text
is schema:about of	named entity 'genetic variability' named entity 'lymphocytopenia' named entity 'stimulants' named entity 'heterozygous' named entity 'host immunity' named entity 'homozygosity' named entity 'intensive care' named entity 'single-agent' named entity 'clinical trials' named entity 'secondary lymphoid tissues' named entity 'high-risk' named entity 'HLA' named entity 'high levels' named entity 'PD-1 inhibitors' named entity 'COVID' named entity 'immunoglobulin' named entity 'HLA' named entity 'IL-6' named entity 'COVID-19' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'anti-PD-1' named entity 'viral infections' named entity 'first-line' named entity 'mortality rate' named entity 'IL-10' named entity 'adverse events' named entity 'heterozygosity' named entity 'genotypes' named entity 'COVID' named entity 'lymphocytopenia' named entity 'serum' named entity 'PD-L1' named entity 'adverse events' named entity 'immune responses' named entity 'IL-6R' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'ICIs' named entity 'sepsis' named entity 'anti-PD-1' named entity 'ICI' named entity 'TNF-α' named entity 'influenza' named entity 'lymphocyte' named entity 'COVID-19' named entity 'COVID' named entity 'HLA' named entity 'influenza' named entity 'mucin' named entity 'ICIs' named entity 'checkpoint blockade' named entity 'critically ill' named entity 'PD-1' named entity 'pneumonitis' named entity 'Immune checkpoint inhibitors' named entity 'physiology' named entity 'PHYSIOLOGY' named entity 'PRE' named entity 'COVID-19' named entity 'PROOF' named entity 'TREATMENT' named entity 'INHIBITORS' named entity 'JOURNAL ' named entity 'APPROACH' named entity 'CHECKPOINT' named entity 'IMMUNE' named entity 'DRIVEN' named entity 'COVID-19'
is part of of	covid:4db3607a0dea04c4e1c3da4ae5bdd39a8435c9f1#body_text While confirmed cases of infections of the deadly coronavirus disease 2019 (COVID-19) have exceeded 4.7 million globally, scientists are pushing forward with efforts to develop vaccines and treatments in an attempt to slow the pandemic and lessen the disease’s damage. Although no proven effective therapies to treat COVID-19 patients or for managing their complications currently exist, the rapidly expanding knowledge regarding severe acute respiratory syndrome–coronavirus 2 and its interplay with hosts provide a significant number of potential drug targets, and the potential to repurpose drugs already tested in other diseases. Herein we report the biological rationale of immuno-activating drugs and a brief summary of literature data on the potential therapeutic value of immune checkpoint inhibitors that have been recently tested beyond cancer treatment for their potential to restore cellular immuno-competence. Immune checkpoint inhibitors: A physiology-driven approach to the treatment of COVID-19

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software